Jan 142011
 

Researchers from the Karolinska Institute in Stockholm, Sweden, report in last month’s issue of the journal Brain, on the postmortem examination of the first-ever person with Alzheimer’s to be followed prospectively by positron emission tomography using Pittsburgh Compound B (PIB-PET), which allows visualization of amyloid plaques.

They analyzed the brain of a woman with Alzheimer’s who had volunteered for the first PET-PIB scan ever performed. She received an additional PIB scan two years later, and three PET scans using fluorodeoxyglucose (FDG), a marker for glucose use and therefore brain metabolism. Over the eight years she was studied, the woman’s score on the Mini-Mental State Examination declined from a near-normal score of 27 down to five. The FDG PET scan data showed that her brain’s glucose metabolism decreased in parallel with her cognitive abilities. By contrast, the amyloid signal as seen by PIB PET, already high at first examination, showed little change over two years during which her cognition declined steeply. This pattern matches data from other recent studies, in which amyloid deposits in the brain increase during the mild cognitive impairment (MCI) stage of Alzheimer’s, but seem to plateau during the dementia stage of Alzheimer’s.

Postmortem examination confirmed the patient’s diagnosis of pure Alzheimer’s disease. Interestingly, the researchers found that the density of a certain receptor in the brain, which binds to acetylcholine, and known to be involved in learning and memory, was lower in brain regions with the highest amyloid, suggesting an interaction.

This study provides further evidence that amyloid deposits appear to reach a plateau early in the disease course, when patients experience very mild symptoms or no symptoms at all. Moreover, it suggests that amyloid may be negatively affecting receptors involved in learning and memory, before it has deposited into plaques.

Michael S. Rafii, M.D., Ph.D.
Associate Medical Core Director, Alzheimer’s Disease Cooperative Study
This post originally appeared in Alzheimer’s Insights, an ADCS Blog.

Learn More

  2 Responses to “The Amyloid Plateau”

  1. I just lost my 77 year old Aunt Carol Petroski to Alzheimers on the 29th of January, 2011. I lost my father July 23rd 2007 and his aunt several years earlier. This illness is devestating our family and I plead with you to make a great breakthrough and course of treatment soon since i and my generation will not have to end our lives in this horrible theft of our minds.What can I do to find out if I carry the gene so that i can start doing what ever neccesary to prevent it or stop it in its tracks?

  2. There is a genetic test, which looks at the ApoE gene. This test is now covered by medicare, and can help evaluate one's risks for developing AD.

 Leave a Reply

(required)

(required)

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Alz.org main site  |  Research  |  Advocacy  |  Care and support  |  Message boards  |  Disclaimer  |  Donate  |  Contact us  |  Sign up for e-news
© 2011 Alzheimer's Association | Blog Suffusion theme by Sayontan Sinha